Roche is paying Alector $100 million upfront in a new partnership focused on neuroscience and Parkinson’s disease efforts. The deal arrives amid shifting collaboration dynamics at large biopharma as companies recalibrate prior licensing arrangements and seek new internal/external bets in neurodegeneration.